BioLineRx Ltd.

What they do

BioLineRx is a clinical-stage biopharmaceutical company that develops and commercializes novel therapies, primarily in oncology. Its lead product candidates are based on its proprietary platform for targeting the CXCR4 pathway. The company operates from Israel and is listed on the Nasdaq Capital Market via American Depositary Shares, each representing 600 ordinary shares.

Revenue drivers

• Aphexda (motixafortide) — A potential commercial product for stem cell mobilization in multiple myeloma; if approved, it would be a key revenue source, but the filing does not provide sales figures.
• Pipeline collaborations — Licensing and collaboration agreements, such as with Guangzhou Gloria Biosciences and Hong Seng Technology Limited (dated August 27, 2023), could generate milestone payments or royalties, though not yet material.
• Grants and other income — The company has historically received non-dilutive funding from Israeli government grants; no current amounts are disclosed in this excerpt.

Recent performance

The filing is a Form 20-F/A for the fiscal year ended December 31, 2025, but the excerpt does not include financial statements or specific figures. No revenue or loss numbers are provided in the provided text. The company had 2,610,814,390 ordinary shares outstanding as of March 8, 2026. The original report was filed March 23, 2026, and this amendment solely revises an auditor consent.

Strategy

The strategy is to advance its lead product candidates through clinical development and toward commercialization in the oncology space. The company has entered into licensing agreements with Asian partners (e.g., Guangzhou Gloria Biosciences, Hong Seng Technology) to expand geographic reach. It maintains a pipeline of assets and actively manages its capital structure through equity offerings and loan facilities (e.g., with Kreos Capital). It is also focused on executing on regulatory filings and potential approvals.

Risks

• Clinical and regulatory risk — No product has received regulatory approval, and failure in trials or delays in approvals could prevent or postpone commercialization.
• Liquidity and dilution risk — The company relies on equity raises and debt (e.g., Kreos loan) to fund operations; future capital raises may dilute existing shareholders.
• Dependence on partners — Revenue and development progress may depend on collaborations with third parties, such as the license with Guangzhou Gloria and Hong Seng, which involve performance and payment risks.
• Limited commercial experience — The company has no commercial infrastructure, and if a product is approved, it may face challenges in manufacturing, marketing, and reimbursement.

Outlook

Management's near-term focus is on completing the regulatory process for its lead candidate and advancing clinical trials. The company may seek additional financing through equity or debt to fund operations. The filing does not provide specific guidance or forward-looking statements beyond the amendment's purpose.